12 of 12 Patients Receiving Experimental HCV Protease Inhibitor are undetectable

[Guest guest]

12 of 12 Patients Receiving Experimental HCV Protease InhibitorVX 950 in Combination with Pegasys Plus Ribavirin for 28 Days Experience Undetectable HCV RNA Levels

Results of a Late-Breaker study to be presented today (May 23, 2006) at DDW 2006 demonstrate that 12 of 12 patients with HCV genotype 1 receiving the investigational HCV protease inhibitor (PI) VX-950 in combination with peginterferon alfa-2a (Pegasys) and ribavirin for 28 days experienced undetectable HCV RNA levels.

In addition, 11 of the 12 patients have maintained undetectable HCV RNA levels after 12 weeks of follow-on therapy.

No patient experienced viral breakthrough during 28 days of VX-950 dosing. All patients completed dosing with no evidence of serious adverse events. The reported adverse events are typical of those associated with peginterferon alfa and ribavirin combination therapy.

Full Article

Regards, Vergelsalvagetherapies dot org